A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

• Adult women (≥ 18 years of age) with at least one visit with a breast cancer ICD10 diagnosis code (C50.x)
• Patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage III, stage IV (distant metastases).
• Patients with a laboratory test positive for hormone receptor (HR) and negative for human epithelial growth factor receptor 2 (HER2) before or up to 60 days after advanced/metastatic breast cancer diagnosis date.

• HR-positive is defined as any positive test for estrogen receptor or progesterone receptor.
• HER2-negative is defined as any HER2-negative test and the absence of a positive test (immunohistochemistry positive (3+), fluorescence in situ hybridization positive/amplified).
• Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer

Exclusion criteria

Patients meeting any of the following criteria will not be included in the study:

• Breast cancer with HR-negative and HER2-positive on laboratory testing.
• More than a 90-day gap between breast cancer diagnosis date and next visit.
• Patients who treated as off-label